

Poster Abstract Tracks/Topics (Review Groups)

There are five robust tracks covering all aspects of the pharmaceutical sciences. Each track is divided into two subtracks; Biomolecular and Chemical.

IMPORTANT Note: in the submission site, the structure below; Track, Subtrack, Primary Topic, and Subtopic, are referred to as Review Groups. You will be prompted to select the Review Group that best fits your abstract. For screener applications, you will choose all that apply to your expertise.

Review Group (Track/Topic) Selection Process


1. Select the Track that best fits your research. (*see below*)

- * Preclinical Development
- * Bioanalytics
- * Clinical Pharmacology
- * Manufacturing and Bioprocessing
- * Formulation and Quality

2. Select the Subtrack (Biomolecular or Chemical).

3. Select the Primary Topic that best fits your research.

4. From your Primary Topic, select the best Subtopic for your research. If no listed term fits your research, select 'Other'. (*Note: There may not be a subtopic available for your Primary Topic.*)

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC
 Bioanalytics	Biomolecular	ADCs and Peptide Quantification	Electrospray Ionization
			Hybrid LBA/LCMS
			Ligand Binding Assay (LBA)
			Other
		Bioanalytical Innovations and Applications	
		Biomarker Quantification	Biomarker/Pharmacodynamic Measurement
			Methods to Assess Disease Heterogeneity
			Target Engagement/Receptor Occupancy
			Technologies other than LBA and Mass Spec (e.g., Flow, PCR)
			Other
		Drug Quantification	Endogenous Homologs Quantification
			Other Methods/Techniques



Bioanalytics

Biomolecular (continued)	Drug Quantification (continued)	Pharmacokinetic Measurements - Intact
		Pharmacokinetic Measurements - Free
		Pharmacokinetic Measurements - Surrogate
		Pharmacokinetic Measurements - Total
		Pharmacokinetic Measurements - Other
		Post-Marketing Commitment
		Therapeutic Drug Monitoring
	Immunogenicity	ADA Test Methods
		Cell-Based Methodologies
		Immunogenicity Risk Assessments
		Neutralizing Antibody Methods
		Other
	In Vivo and Ex Vivo Biotransformation	Evaluation of Biotransformation In Vivo
		Impact of Biotransformation on Immunogenicity
		Impact of Biotransformation on PK
		Molecule Variants Quantification Ex Vivo
	Life Cycle Management of Bioanalytical Methods	Collaboration with Other Partners (Co-development)
		General Life Cycle Management
		Methods Transfer and CRO Management
		Other
	Novel Modalities	ADCs
		Alternative Scaffold
		CAR-T
		Cell-Based Therapy
		Encapsulated Drugs (Lipid, Nanoparticle, and Viral Vectors)
		Multi-specific Antibodies
		Nanoparticle Based Modalities
		Oligos, RNAs and Locked Nucleic Acids
	Other	
	Reagents and Reference Standards	Life Cycle Management
		Quality Control and Characterization
		Stability
		Other
Regulations (BMV/GLP/GCP/CLIA)	Biomarkers	
	Drug (and Metabolites)	
	GCP/GLP Compliance for Bioanalytical Labs	
	General Topics	
	ICH	
	Immunogenicity	
Samples and Reagent Stability		




Bioanalytics

Biomolecular (continued)	Regulations (BMV/GLP/GCP/CLIA)	Bioanalytics Risk Assessment and Strategy (Tiered Strategies)
		Other
	Samples and Laboratory Management	Laboratory Information Management System (LIMS)
		Microsampling and Dried Blood Spots
		Post-Collection Sample Condition and Record Management
Other		
Vaccines		Methods/Techniques
		Protective Titer Assessment
		Other
Chemical	ADCs and Peptide Quantification	Electrospray Ionization
		Hybrid LBA/LCMS
		Ligand Binding Assay (LBA)
		Other
	Analyte Stability	Ex Vivo
		In Vitro
		Other
	Applications	
	Biomarker Quantification	Biomarker/Pharmacodynamic Measurement
		Methods to Assess Disease Heterogeneity
		Target Engagement/Receptor Occupancy
		Technologies Other than Mass Spec (e.g., PCR)
		Other
	Drug Quantification	Endogenous Homologs Quantification
		Other Methods/Techniques
		Pharmacokinetic Measurements
		Therapeutic Drug Monitoring
	Immunogenicity	ADA Test Methods
		Other
	In Vivo and Ex Vivo Biotransformation	CYP450 Assessment
		Evaluation of Biotransformation In Vitro or In Vivo
Impact of Biotransformation on Immunogenicity		
Impact of Biotransformation on PK		
Metabolite Quantification		
	Other	
Life Cycle Management of Bioanalytical Methods	Collaboration with Other Partners (Co-development)	
	General Life Cycle Management	
	Methods Transfer and CRO Management	
	Other	



Bioanalytics

Chemical (continued)	Novel Modalities	Alternative Scaffold
		Encapsulated Drugs (Lipid, Nanoparticle and Viral Vectors)
		Multispecific Antibodies
		Nanoparticle Based Modalities
		Oligos and Locked Nucleic Acids
	Other	
	Reagents and Reference Standards	Life Cycle Management
		Quality Control and Characterization
		Stability
		Other
	Regulations (BMV/GLP/GCP/CLIA)	Biomarkers
		Drug (and Metabolites)
		GCP/GLP Compliance for Bioanalytical Labs
		General Topics
		ICH
		Immunogenicity
		Samples and Reagent Stability
		Bioanalytics Risk Assessment and Strategy (Tiered Strategies)
	Other	
	Samples and Laboratory Management	Informed Consent
Laboratory Information Management Systems (LIMS)		
Microsampling and Dried Blood Spots		
Post-collection Sample Condition and Record Management		
Other		

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC
 Clinical Pharmacology	Biomolecular	Biostatistical Methodologies	Bayesian Methods
			Regulatory Recommendations
			Statistical Analysis Models
			Statistical Reporting
			Tools/Software
		Other	
		Clinical Trials	Designs and Methodology
			Dosing Strategies
			Ethics in Clinical Trials
			Modeling and Simulation
			Monitoring
			Patient Stratification
			Regulatory Guidance
		Other	
		Immunogenicity	ADA
			Clinical Relevance
			Neutralizing Antibody
			Other
		In Vitro Studies	ADME
			Biomarkers/Pharmacodynamic Measures
			Blood to Plasma Partitioning
			Drug Transport and Drug Interactions
			Genetic Variation/PGx Testing
			Protein Binding
		Other	
		Modalities	ADCs
			Alternative Scaffold
			CAR-T
Cell-Based Therapy			
Encapsulated Drugs (Lipid, Nanoparticle and Viral Vectors)			
Multispecific Antibodies			
Nanoparticle-Based			
Oligos, RNAs and Locked Nucleic Acids			
Vaccines			
Other			



Clinical Pharmacology

Biomolecular

Modeling and Simulation


- Absorption Model
- Allometric Scaling
- Comparator Modeling
- Decision Making
- Dose Project/Selection/Justification
- Imaging Based Approach
- In Vivo-In Vitro Correlation (IVIVC) Modeling
- Maternal/Fetal PK Model
- Pediatric Model
- Pharmacometrics
- Physiologically Based Pharmacokinetics (PBPK) Model
- PK/PD Modeling
- Population PK Modeling
- Quantitative Systems Pharmacology (QSP)
- Tools/Software
- Other


Regulatory Guidance/Submissions


- CDISC
- Clinical Study Reports (CSRs)
- Clinical Trial Protocols
- CTD/eCTD Models 1 to 5
- Data Management
- FDA/EMA/PMDA Meetings
- Labeling
- NDA/BLA/ANDA Submissions
- Safety
- Other

Type of Human Studies

- Bioequivalence/Biosimilars
- Diseased Population
- Drug-Drug Interaction (DDI)
- First-Time-in-Human (FTIH)
- Food Effect
- Geriatric
- Multiple Ascending Dose (MAD)
- Pediatric
- Radio-Labeled Mass Balance and ADME
- Relative and Absolute BA
- Single Ascending Dose (SAD)
- Thorough QT/QTc (TQT)
- Other

 Clinical Pharmacology	Chemical	Biostatistical Methodologies	Bayesian Methods
			Regulatory Recommendations
			Statistical Analysis Models
			Statistical Reporting
			Tools/Software
		Other	
		Clinical Trials	Designs and Methodology
			Dosing Strategies
			Ethics in Clinical Trials
			Modeling and Simulation
			Monitoring
			Patient Stratification
			Regulatory Guidance
		Other	
		In Vitro Studies	ADME
			Biomarkers/Pharmacodynamic Measures
			Blood to Plasma Partitioning
			Drug Transport and Drug Interactions
			Genetic Variation/PGx Testing
			Protein Binding
		Other	
		Modeling and Simulation	Absorption Model
			Allometric Scaling
			Comparator Modeling
			Decision Making
			Dose Project/Selection/Justification
			Imaging Based Approach
			In Vivo-In Vitro Correlation (IVIVC) Modeling
			Maternal/Fetal PK Model
			Pediatric Model
			Pharmacometrics
			Physiologically Based Pharmacokinetics (PBPK) Model
			PK/PD Modeling
			Population PK Modeling
			Quantitative Systems Pharmacology (QSP)
Tools/Software			
Other			

 Clinical Pharmacology	Chemical (continued)	Regulatory Guidance/Submissions	CDISC
			Clinical Study Reports (CSRs)
			Clinical Trial Protocols
			CTD/eCTD Models 1 to 5
			Data Management
			FDA/EMA/PMDA Meetings
			Labeling
			NDA/BLA/ANDA Submissions
			Safety
			Other
	Type of Human Studies	Bioequivalence/Biosimilars	
		Diseased Population	
		Drug-Drug Interaction (DDI)	
		First-Time-in-Human (FTIH)	
		Food Effect	
		Geriatric	
		Multiple Ascending Dose (MAD)	
		Pediatric	
		Radio-Labeled Mass Balance and ADME	
		Relative and Absolute BA	
Single Ascending Dose (SAD)			
Thorough QT/QTc (TQT)			
Other			

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC
 Formulation and Quality	Biomolecular	Administration	In-Use Compatibility
			Nasal/Pulmonary
			Ocular
			Otic
			Strategies
			Trans-dermal
			Other
		Analytical	(Sub)Visible Particles
			Excipients
			Impurities
			Modality Specific Methods - Cell Therapy
			Modality Specific Methods - Free Oligonucleotide
			Modality Specific Methods - Gene Therapy
			Modality Specific Methods - Protein
			Modality Specific Methods - Vaccine/Tolerance Induction
			Modality Specific Methods - Other
			New Technology
		Drug Delivery	Potency/Bioassay
			Other
			Extended Release (Non-implant)
			Implants
			Other Routes of Administration - Ocular
			Other Routes of Administration - Otic
		Other Routes of Administration - Transdermal and Topical	
Other Routes of Administration - Other			
Other			
Drug Delivery, Devices, and Drug Device	Design Control		
	Hardware		
	Human Factor Engineering		
	New Delivery Technologies		
	Patient-Centric Development		
Software			
Formulation	Cell Therapy		
	Free Oligonucleotide		
	Gene Therapy		
	Protein - Developability Assessment		
	Protein - Excipients		
	Protein - Topics		



Formulation and Quality

**Biomolecular
(continued)**

Formulation (continued)

- Protein - Syringes
- Protein - High-Throughput Screening
- Protein - Lyo
- Protein - Other
- Vaccine/Tolerance Induction
- Other

Primary Packaging

- Compatibility
- Container Closure Integrity
- Extractables/Leachables
- New Materials

Regulatory Considerations

- (Sub)visible Particles
- Accelerated Approval Pathways
- Bioequivalence
- Biosimilars
- Innovative Technologies
- Inspections and GMP's
- Large Market Developments
- New Regulations and Guidances
- Risk Assessment Implementation
- Smaller Market Developments
- Stability Requirements

Chemical

Analytical

- Drug Release Measurement - Biorelevant Dissolution
- Drug Release Measurement - Cascade Impaction
- Drug Release Measurement - Dissolution
- Drug Release Measurement - Forms
- Drug Release Measurement - Other
- Excipients
- Impurities and Degradation - Forced Degradation
- Impurities and Degradation - Impurity Quantitation
- Impurities and Degradation - In Silico Predecision of Stability
- Impurities and Degradation - Other
- Method Development Strategies
- New Analytical Technologies
- Process Analytical Technology and Continuous Release Testing
- Other

Biopharmaceutics

- BCS, DCS
- Bioequivalence (also Regulatory)
- Comparability Assessments
- IVIVC
- Predictive Modeling



Formulation and Quality

**Chemical
(continued)**

Biopharmaceutics (continued)

Other

Drug Delivery

- Extended Release (Non-implant)
- Implants
- Other Routes of Administration - Ocular
- Other Routes of Administration - Otic
- Other Routes of Administration - Transdermal and Topical
- Other Routes of Administration - Other
- Other

Drug Delivery, Devices, and Drug Device

- Design Control
- Hardware
- Human Factor Engineering
- New Delivery Technologies
- Patient-Centric Development
- Software

Formulation


- Amorphous and Co-crystal Systems
- Bioavailability Enhancement
- Drug Substance Properties
- Excipients
- Fixed Dose Combinations
- Inhalation and Nasal
- Oral - Immediate Release
- Oral - Modified Release
- Parenterals
- Preformulation
- Special Populations

Primary Packaging

- Compatibility
- Container Closure Integrity
- Extractables/Leachables
- New Materials

Regulatory Considerations

- (Sub)visible Particles
- Accelerated Approval Pathways
- Bioequivalence
- Biosimilars
- Innovative Technologies
- Inspections and GMP's
- Large Market Developments
- New Regulations and Guidances
- Risk Assessment Implementation
- Smaller Market Developments
- Stability Requirements

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC
 Manufacturing and Bioprocessing	Biomolecular	Automation	Computer Validation Other
		Biosimilar Manufacturing	Biosimilarity Assessment Patent Protection Other
		Drug Product Manufacturing and Development	Aseptic Technologies and Sterilization - Filling
			Aseptic Technologies and Sterilization - Filtration
			Aseptic Technologies and Sterilization - Mixing
			Aseptic Technologies and Sterilization - Other
			Cell Therapies
			Freezing and Thawing
			Lyophilization and Drying Technologies
			Manufacturing and Assembly of Drug/Device Combinations
			Manufacturing of Drug Delivery Systems
			Primary Packaging - Container Closure Integrity
			Primary Packaging - Syringes
			Primary Packaging Vials
			Primary Packaging - Other
			Process Optimization
			Protein Aggregation during Processing and Immunogenicity
			Secondary Packaging
		Storage Considerations	
		Vaccines	
		Viral and Non-viral Vectors and Gene Therapy	
		Visible and Subvisible Particles	
		Visual Inspection	
		Other	
		Drug Substance Manufacturing and Development	API Packaging and Storage
			Cell Line Development
			Cell Therapies
Clonality Assessments			
Expression Systems			
Genetic and Cell Line Engineering			
Mammalian Cell Fermentation			
Media Development			
Microbial/Yeast Fermentation			
Process Optimization			
Protein Aggregation during Processing and Immunogenicity			



**Biomolecular
(continued)**

Drug Substance Manufacturing and Development (continued)	Purification and Virus Removal
	Vaccines
	Viral and Non-viral Vectors and Gene Therapy
General Aspects and Strategies	Other
	Change Control
	CMO Management
	Drug Master Files
	Drug Substance and Drug Product Shipment
	Electronic Records
	Handling Control Substances (DEA)
	Inspections and GMP
	Lean Manufacturing
	Life Cycle Management
	Manufacturing Economics
	Materials Management and Warehousing
	Regulatory Strategy
	Supply Chain
Other	
Health, Safety, and Environment	Containment and Isolators
	High-Potent Drug Manufacturing
	OEL and PDE
	Other
Innovative/Novel Processing Technologies and Concepts	For Use in Drug Product Manufacture
	For Use in Drug Substance Manufacture
	Other
Integrated and Continuous Processing and Manufacturing	For Use in Drug Product Manufacture
	For Use in Drug Substance Manufacture
	Other
Manufacture of Clinical Supplies	Blinding of Comparator Drugs
	Phase Appropriate GMP
	Other
Plant Engineering and Maintenance	Clean Media
	Facility Design
	Media
	Media Fills
	Modeling and Scheduling Multiproduct Batch Plants
	Modular Manufacturing
	Plant Incident Investigations
	Other



Biomolecular (continued)	Process Design and Controls	Cleaning Validation
		Control of Impurity Formation
		In-Process Controls
		Process Analytical Technology and Parametric/Real-Time Release
		Process Modeling and Simulations
		Process Validation
		QbD and Assessment of Process Parameters
		Scale-Up/Process Transfers
		Statistical Process Controls and Six Sigma
		Use of Prior Knowledge and Risk-Based Approaches
		Other
	Single-Use and Disposable Systems	For Use in Drug Product Manufacture
		For Use in Drug Substance Manufacture
		Leachables and Extractables
		Other
Chemical	Automation	Computer Validation
		Other
	Drug Product Manufacturing and Development	Aseptic Technologies and Sterilization - Filling
		Aseptic Technologies and Sterilization - Filtration
		Aseptic Technologies and Sterilization - Mixing
		Aseptic Technologies and Sterilization - Other
		Freezing and Thawing
		Liquids Manufacture - Oral and Topical Liquids
		Liquids Manufacture - Other
		Lyophilization and Drying Technologies
		Manufacturing and Assembly of Drug/Device Combinations
		Manufacturing of Aerosols and DPI
		Manufacturing of Drug Delivery Systems
		Primary Packaging - Blisters
		Primary Packaging - Bottles
		Primary Packaging - Container Closure Integrity
		Process Optimization
		Secondary Packaging
		Semi-solids Manufacture - Cremes
		Semi-solids Manufacture - Liposomes, Solid Lipid Nanoparticles
		Semi-solids Manufacture - Other
		Solids Manufacture - Capsules
	Solids Manufacture - Powders	
	Solids Manufacture - Tablets and Granules	




**Chemical
(continued)**


Drug Product Manufacturing and Development (continued)	Solids Manufacture - Other
	Storage Considerations
	Visual Inspection
	Other
Drug Substance Manufacturing and Development	API Kilo Lab
	API Packaging and Storage
	Control of Impurity Formation
	Crystal Structure/Polymorph Screening
	Crystallization Development
	Filtration
	Genotoxic Impurities
	Milling and Micronization Technologies
	Particle Size Control
	Process Chromatography
	Process Optimization
	Purification
	Other
General Aspects and Strategies	Change Control
	CMO Management
	Drug Master Files
	Drug Substance and Drug Product Shipment
	Electronic Records
	Handling Control Substances (DEA)
	Inspections and GMP
	Lean Manufacturing
	Life Cycle Management
	Manufacturing Economics
	Materials Management and Warehousing
	Regulatory Strategy
	Supply Chain
Other	
Generic Manufacturing	Patent Protection
	Pharmaceutical Equivalence Assessment
	Other
Health, Safety, and Environment	Containment and Isolators
	Explosion Protection
	Green Chemistry
	High-Potent Drug Manufacturing




**Chemical
(continued)**

Health, Safety, and Environment (continued)	OEL and PDE
	Solvent Recovery
	Other
Innovative/Novel Processing Technologies and Concepts	For Use in Drug Product Manufacture
	For Use in Drug Substance Manufacture
	Other
Integrated and Continuous Processing and Manufacturing	For Use in Drug Product Manufacture
	For Use in Drug Substance Manufacture
	Other
Manufacture of Clinical Supplies	Blinding of Comparator Drugs
	Phase Appropriate GMP
	Other
Plant Engineering and Maintenance	Clean Media
	Facility Design
	Media
	Media Fills
	Modeling and Scheduling Multiproduct Batch Plants
	Modular Manufacturing
	Plant Incident Investigations
	Other
Process Design and Controls	Cleaning Validation
	Control of Impurity Formation
	In-Process Controls
	Process Analytical Technology and Parametric/Real-Time Release
	Process Modeling and Simulations
	Process Validation
	QbD and Assessment of Process Parameters
	Scale-Up/Process Transfers
	Statistical Process Controls and Six Sigma
	Use of Prior Knowledge and Risk-Based Approaches
Other	
Single-Use and Disposable Systems	For Use in Drug Product Manufacture
	For Use in Drug Substance Manufacture
	Leachables and Extractables
	Other

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC
 Preclinical Development	Biomolecular	ADME	In Vitro - Metabolizing Enzymes
			In Vitro - Protein Binding
			In Vitro - Transporter
			In Vitro - Other
			In Vivo
			Pharmacokinetics
			Other
		Discovery	Biology - In Silico
			Biology - In Vitro
			Biology - In Vivo
			Biology - Receptor/Target Interactions
			Biology - Target Identification
			Biology - Other
			Biology/Efficacy - In Silico
			Biology/Efficacy - In Vitro
			Biology/Efficacy - In Vivo
			Chemistry - Structure Activity Relationships
			Chemistry - Other
			Conjugation
			Novel Drug Modality
			Payload-Linker Identification/Optimization
			Protein/Gene Engineering and Expression
			Receptor/Target Interactions
			Structure Activity Relationships
			Target Identification and Selection
			Vaccines - Antigen Evaluation
			Vaccines - Disease and Pathogen Evaluation
			Vaccines - Immunogenicity
			Vaccines - Innate/Adaptive Immunity
			Vaccines - Novel Delivery Strategies
		Vaccines - Parasite Biology	
		Vaccines - Adjuvants	
		Vaccines - Other	
Other			
OMICS	Genomics		
	Metabolomics		
	Proteomics		

 Preclinical Development	Biomolecular (continued)	Safety	Cellular and Molecular Toxicity	
			De-risking Strategies	
			Immuno-toxicity	
			IND Enabling Studies	
			Mechanistic Toxicity	
			Screening Toxicity Studies	
		Other		
		Translation	Drug-Drug Interactions	
			Human Dose Projections - Allometric	
			Human Dose Projections - Pharmacokinetics (PBPK)	
	Human Dose Projections - Other			
	Chemical	ADME	Model Based Drug Development	
			PK/PD	
			Other	
			Discovery	In Vitro - Metabolizing Enzymes
				In Vitro - Protein Binding
				In Vitro - Transporter
		In Vitro - Other		
		OMICS	In Vivo	
			Pharmacokinetics	
Other				
Biology - In Silico				
Biology - In Vitro				
Biology - In Vivo				
Biology - Receptor/Target Interactions				
Biology - Target Identification				
Biology - Other				
Chemistry - Structure Activity Relationships				
Chemistry - Other				
In Silico				
In Vitro				
In Vivo				
Novel Drug Modality				
Target Interactions				
Other				
Genomics				
Metabolomics				
Proteomics				

 Preclinical Development	Chemical (continued)	Safety	Cellular and Molecular Toxicology
			De-risking Strategies
			Immuno-toxicity
			IND Enabling Studies
			Mechanistic Toxicity
			Screening Toxicity Studies
			Other
		Translation	Drug-Drug Interactions
			Human Dose Projections - Allometric
			Human Dose Projections - Physiologically Based Pharmacokinetics (PBPK)
			Human Dose Projections - Other
			Model Based Drug Development
			PK/PD
			Other